CXCR3 and rheumatoid arthritis: RA patient–derived B cells had the capacity to invade in response to RA synovial biopsy-conditioned media; however, upon treatment with the CXCR3 antagonist AMG487, B cell invasion was significantly reduced (P = 0.03) (Figure 3F).